Westpac Banking Corp increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 23.7% during the second quarter, Holdings Channel reports. The firm owned 49,993 shares of the biopharmaceutical company’s stock after buying an additional 9,584 shares during the period. Westpac Banking Corp’s holdings in Celgene Corp. were worth $4,782,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. Legal & General Group Plc raised its position in Celgene Corp. by 1.4% in the first quarter. Legal & General Group Plc now owns 3,325,160 shares of the biopharmaceutical company’s stock worth $332,817,000 after buying an additional 46,095 shares during the period. Nuveen Asset Management LLC raised its position in Celgene Corp. by 36.3% in the first quarter. Nuveen Asset Management LLC now owns 308,169 shares of the biopharmaceutical company’s stock worth $30,844,000 after buying an additional 82,087 shares during the period. Atwood & Palmer Inc. raised its position in Celgene Corp. by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock worth $15,420,000 after buying an additional 2,543 shares during the period. Fisher Asset Management LLC raised its position in Celgene Corp. by 3.0% in the second quarter. Fisher Asset Management LLC now owns 204,128 shares of the biopharmaceutical company’s stock worth $21,109,000 after buying an additional 5,968 shares during the period. Finally, First Republic Investment Management Inc. raised its position in Celgene Corp. by 5.6% in the first quarter. First Republic Investment Management Inc. now owns 455,197 shares of the biopharmaceutical company’s stock worth $45,562,000 after buying an additional 24,245 shares during the period. 77.75% of the stock is owned by institutional investors and hedge funds.

Celgene Corp. (NASDAQ:CELG) opened at 109.83 on Thursday. The firm has a market capitalization of $85.13 billion, a P/E ratio of 46.42 and a beta of 1.31. The stock’s 50 day moving average price is $110.08 and its 200 day moving average price is $105.06. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $128.39.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.05. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. During the same quarter in the prior year, the business posted $1.23 EPS. The business’s revenue for the quarter was up 20.9% on a year-over-year basis. On average, equities analysts expect that Celgene Corp. will post $5.71 EPS for the current year.

CELG has been the subject of a number of analyst reports. Robert W. Baird restated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corp. in a research report on Tuesday, September 13th. BMO Capital Markets restated an “outperform” rating and issued a $141.00 price target on shares of Celgene Corp. in a research report on Tuesday, August 23rd. Cowen and Company restated an “outperform” rating and issued a $150.00 price target on shares of Celgene Corp. in a research report on Thursday, August 25th. Bank of America Corp. restated a “buy” rating and issued a $128.00 price target on shares of Celgene Corp. in a research report on Friday, September 16th. Finally, Jefferies Group restated a “buy” rating and issued a $138.00 price target on shares of Celgene Corp. in a research report on Sunday, July 10th. Four analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $138.10.

In related news, insider Robert J. Hugin sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the transaction, the insider now owns 1,022,201 shares in the company, valued at approximately $112,442,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,710 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total value of $1,033,532.40. Following the transaction, the director now owns 72,142 shares in the company, valued at approximately $7,678,794.48. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.